Short Interest in Revelation Biosciences, Inc. (NASDAQ:REVB) Expands By 38.1%

Revelation Biosciences, Inc. (NASDAQ:REVB) was the target of a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 63,400 shares, a growth of 38.1% from the January 15th total of 45,900 shares. Currently, 12.1% of the shares of the stock are short sold. Based on an average daily volume of 237,200 shares, the short-interest ratio is currently 0.3 days.

Revelation Biosciences Stock Up 2.9 %

Shares of NASDAQ REVB traded up $0.12 during mid-day trading on Friday, hitting $4.28. 69,595 shares of the company’s stock traded hands, compared to its average volume of 160,792. The company’s 50-day moving average is $5.99 and its two-hundred day moving average is $11.54. Revelation Biosciences has a 1 year low of $3.34 and a 1 year high of $69.44.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.